Retroviral hybrid LTR vector strategy: Functional analysis of LTR elements and generation of endothelial cell specificity

Gene Therapy

Volumn 11, Issue 9, 2004, Pages 775-783

  Richardson, T B ^a   Kaspers, J ^a   Porter, C D ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

Author keywords

Endothelial cell specificity; Hybrid LTR; Transcriptional targeting; U3 deletions

Indexed keywords

DNA FRAGMENT; INTERCELLULAR ADHESION MOLECULE 2; RETROVIRUS VECTOR; VASCULAR TARGETING AGENT; VASCULOTROPIN RECEPTOR; VASCULOTROPIN RECEPTOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING SITE; BREAST CELL; CANCER THERAPY; CELL LINE; CELL SPECIFICITY; CONTROLLED STUDY; DNA RESPONSIVE ELEMENT; DRUG ACTIVITY; DRUG DESIGN; DRUG SAFETY; DRUG SPECIFICITY; ENDOTHELIUM CELL; ENHANCER REGION; FUNCTIONAL ASSESSMENT; GENE ACTIVATION; GENE DELETION; GENE EXPRESSION REGULATION; GENE INSERTION; GENE SEQUENCE; GENE TARGETING; GENE THERAPY; GENE VECTOR; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LONG TERMINAL REPEAT; MICROVASCULATURE; MOUSE; NONHUMAN; PREVENTION; PRIORITY JOURNAL; PROMOTER REGION; PROVIRUS; SUBCUTANEOUS TISSUE TUMOR; TARGET CELL; TRANSCRIPTION REGULATION; TRANSGENE; TUMOR CELL; TUMOR XENOGRAFT; VIRUS GENE; VIRUS HYBRID; VIRUS TRANSCRIPTION;

ANIMALS; ANTIGENS, CD; CELL ADHESION MOLECULES; ENDOTHELIAL CELLS; FEMALE; GENE EXPRESSION; GENE TARGETING; GENE THERAPY; GENETIC VECTORS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PROMOTER REGIONS (GENETICS); RETROVIRIDAE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TERMINAL REPEAT SEQUENCES; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 2442661439     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3302220     Document Type: Article

References (48)

1. Holmgren L, O'Reilly MS, Folkman J. Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1995; 1: 149-153.
2. Fong TA et al. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106.
3. Miki T et al. Angiogenesis inhibitor TNP-470 inhibits growth and metastasis of a hormone-independent rat prostatic carcinoma cell line. J Urol 1998; 160: 210-213.
4. Mitjans F et al. An anti-alpha v-integrin antibody that blocks integrin function inhibits the development of a human melanoma in nude mice. J Cell Sci 1995; 108: 2825-2838.
5. O'Reilly MS, Holmgren L, Chen C, Folkman J. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996; 2: 689-692.
6. O'Reilly MS et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88: 277-285.
7. Griggs J, Metcalfe JC, Hesketh R. Targeting tumour vasculature: the development of combretastatin A4. Lancet Oncol 2001; 2: 82-87.
8. Denekamp J. Endothelial cell proliferation as a novel approach to targeting tumour therapy. Br J Cancer 1982; 45: 136-139.
9. Mavria G, Porter CD. Reduced growth in response to ganciclovir treatment of subcutaneous xenograffs expressing HSV-tk in the vascular compartment. Gene Therapy 2001; 8: 913-920.
10. Granger SW, Fan H. In vivo footprinting of the enhancer sequences in the upstream long terminal repeat of Moloney murine leukemia virus: differential binding of nuclear factors in different cell types. J Virol 1998; 72: 8961-8970.
11. Speck NA, Baltimore D. Six distinct nuclear factors interact with the 75-base-pair repeat of the Moloney murine leukemia virus enhancer. Mol Cell Biol 1987; 7: 1101-1110.
12. Emerman M, Temin HM. Genes with promoters in retrovirus vectors can be independently suppressed by an epigenetic mechanism. Cell 1984; 39: 449-467.
13. Cone RD, Weber-Benarous A, Baorto D, Mulligan RC. Regulated expression of a complete human beta-globin gene encoded by a transmissible retrovirus vector. Mol Cell Biol 1987; 7: 887-897.
14. Nakajima K et al. An improved retroviral vector for assaying promoter activity. Analysis of promoter interference in pIP211 vector. FEBS Lett 1993; 315: 129-133.
15. Halene S et al. Improved expression in hematopoietic and lymphoid cells in mice after transplantation of bone marrow transduced with a modified retroviral vector. Blood 1999; 94: 3349-3357.
16. Robbins PB et al. Increased probability of expression from modified retroviral vectors in embryonal stem cells and embryonal carcinoma cells. J Virol 1997; 71: 9466-9474.
17. Prince VE, Rigby PW. Derivatives of Moloney murine sarcoma virus capable of being transcribed in embryonal carcinoma stem cells have gained a functional Sp1 binding site. J Virol 1991; 65: 1803-1811.
18. Moore KA et al. Evaluation of lymphoid-specific enhancer addition or substitution in a basic retrovirus vector. Hum Gene Ther 1991; 2: 307-315.
19. Ferrari G et al. A retroviral vector containing a muscle-specific enhancer drives gene expression only in differentiated muscle fibers. Hum Gene Ther 1995; 6: 733-742.
20. Fassati A et al. Insertion of two independent enhancers in the long terminal repeat of a self-inactivating vector results in high-titer retroviral vectors with tissue-specific expression. Hum Gene Ther 1998; 9: 2459-2468.
21. Diaz RM, Eisen T, Hart IR, Vile RG. Exchange of viral promoter/enhancer elements with heterologous regulatory sequences generates targeted hybrid long terminal repeat vectors for gene therapy of melanoma. J Virol 1998; 72: 789-795.
22. Vile RG et al. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter. Virology 1995; 214: 307-313.
23. Grande A et al. Transcriptional targeting of retroviral vectors to the erythroblastic progeny of transduced hematopoietic stem cells. Blood 1999; 93: 3276-3285.
24. Indraccolo S et al. Modulation of Moloney leukemia virus long terminal repeat transcriptional activity by the murine CD4 silencer in retroviral vectors. Virology 2000; 276: 83-92.
25. Jager U, Zhao Y, Porter CD. Endothelial cell-specific transcriptional targeting from a hybrid long terminal repeat retrovirus vector containing human prepro-endothelin-1 promoter sequences. J Virol 1999; 73: 9702-9709.
26. Mavria G, Jager U, Porter CD. Generation of a high titre retroviral vector for endothelial cell-specific gene expression in vivo. Gene Therapy 2000; 7: 368-376.
27. Hanahan D. Signaling vascular morphogenesis and maintenance. Science 1997; 277: 48-50.
28. Boocock CA et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 1995; 87: 506-516.
29. Hatva E et al. Expression of endothelial cell-specific receptor tyrosine kinases and growth factors in human brain tumors. Am J Pathol 1995; 146: 368-378.
30. Kranz A, Mattfeldt T, Waltenberger J. Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer. Int J Cancer 1999; 84: 293-298.
31. Anastassiou G et al. Platelet endothelial cell adhesion molecule-1 (PECAM-1): a potential prognostic marker involved in leukocyte infiltration of renal cell carcinoma. Oncology 1996; 53: 127-132.
32. Morishita K, Johnson DE, Williams LT. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-specific gene expression. J Biol Chem 1995; 270: 27948-27953.
33. Patterson C et al. Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor. J Biol Chem 1995; 270: 23111-23118.
34. Cowan PJ et al. Targeting gene expression to endothelial cells in transgenic mice using the human intracellular adhesion molecule 2 promoter. Transplantation 1996; 62: 155-160.
35. Martinez E, Chiang CM, Ge H, Roeder RG. TATA-binding protein-associated factor(s) in TFIID function through the initiator to direct basal transcription from a TATA-less class II promoter. EMBO J 1994; 13: 3115-3126.
36. Shibuya M et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5: 519-524.
37. Smale ST. Core promoters: active contributors to combinatorial gene regulation. Genes Dev 2001; 15: 2503-2508.
38. Cowan PJ et al. The human ICAM-2 promoter is endothelial cell-specific in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem 1998; 273: 11737-11744.
39. Schlaeger TM et al. Uniform vascular-endothelial-cell-specific gene expression in both embryonic and adult transgenic mice. Proc Natl Acad Sci USA 1997; 94: 3058-3063.
40. Aitsebaomo J et al. Vezf1 DB1 is an endothelial cell-specific transcription factor that regulates expression of the endothelin-1 promoter. J Biol Chem 2001; 276: 39197-39205.
41. Yu S-F et al. Self-inactivating retroviral vectors designed for transfer of whole genes into mammalian cells. Proc Natl Acad Sci USA 1986; 83: 3194-3198.
42. Kohn DB, Sadelain M, Glorioso JC. Occurrence of leukaemia following gene therapy of X-linked SCID. Nat Rev Cancer 2003; 3: 477-488.
43. Reuss FU, Berdel B, Ploss M, Heber R. Replication of enhancer-deficient amphotropic murine leukemia virus in human cells. Proc Natl Acad Sci USA 2001; 98: 10898-10903.
44. Lunardi-Iskandar Y et al. Tumorigenesis and metastasis of neoplastic Kaposi's sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 1995; 375: 64-68.
45. Cosset F-L et al. High titre packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995; 69: 7430-7436.
46. Ades EW et al. HMEC-1: establishment of an immortalized human microvascular endothelial cell line. J Invest Dermatol 1992; 99: 683-690.
47. Wernert N et al. c-ets1 proto-oncogene is a transcription factor expressed in endothelial cells during tumor vascularization and other forms of angiogenesis in humans. Am J Pathol 1992; 140: 119-127.
48. Porter CD et al. Cationic liposomes enhance the rate of transduction by a recombinant retroviral vector in vitro and in vivo. J Virol 1998; 72: 4832-4840.